Brief: Beyond Cancer Presents Positive Preclinical Data For Ultra-High Concentration Nitric Oxide (UNO) In Combination With Checkpoint Inhibitor Therapy
16/10/2023 14:17
Oct 16 (Reuters) - Beyond Air Inc XAIR.O :
* BEYOND CANCER™ PRESENTS POSITIVE PRECLINICAL DATA FOR
ULTRA-HIGH
CONCENTRATION NITRIC OXIDE (UNO) IN COMBINATION WITH CHECKPOINT
INHIBITOR THERAPY DURING THE 2023 AACR-NCI-EORTC INTERNATIONAL
CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
Source text for Eikon: ID:nGNX4bkZHF
Further company coverage: XAIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyond Air
See all newsBrief: Beyond Air Enters Definitive Agreement To Sell Its NeuroNOS Stake To UNIVO Pharmaceutical Industries In Exchange For Equity And Milestone Payments
Beyond Air Inc reports results for the quarter ended June 30 - Earnings Summary
Beyond Air Q1 net loss slightly widens, reaffirms 2026 outlook
Beyond Air Inc expected to post a loss of $10.80 a share - Earnings Preview
NASDAQ RESUMED AT 04:00 AM